Topic: Hepatology
Conditions
Interventions
Imaging using the Philips EPIQ 7™ Ultrasound System, the Siemens Acuson (ARFI) Ultrasound System, and by Echosens Fibroscan™ (which is currently the best validated technique).
Sponsors
Imperial College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Able and willing to provide written informed consent 2. Aged between 18 and 75 3. Chronic liver disease 4. About to undergo a liver biopsy as part of standard routine clinical care, or if a liver biopsy has recently been performed, and is willing to come in for a specific research visit for the 3 scans 5. Willing to consent to medical notes and diagnostic test results being reviewed, captured, and recorded by the clinical research study team
Exclusion criteria
Exclusion criteria: 1. Unable or unwilling to give written informed consent 2. Aged under 18 or over 75 3. No evidence of liver disease 4. Pregnancy 5. Patients with pacemakers fitted
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To correlate liver stiffness assessed by the Philips EPIQ 7™ Ultrasound System, the Siemens Acuson (ARFI) ultrasound system, and by Echosens Fibroscan™ (which is currently the best validated technique), and compare the results of these 3 imaging techniques to histological results in patients with chronic liver disease of different aetiologies. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cut-off values of the liver stiffness (LS) measurements that correlate to the histological fibrosis stage 2. Variations of the liver stiffness (LS) measurements correlated to different parameters 3. Quality parameters (IQR and SR) for the liver stiffness (LS) measurements 4. Ability of distinguishing non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver disease (NAFLD) | — |
Countries
England, United Kingdom
Contacts
Public ContactClaire Parsonage
Outcome results
None listed